Aspen Neuroscience counsel holds 101,193-share option

The option begins vesting on May 7, 2027, then continues monthly subject to Jeffrey Lee Boerneke's continued service.

Accepted by SEC EDGAR 10/29/2026 - 08:24 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Aspen Neuroscience, Inc. reports that its General Counsel and Secretary, Jeffrey Lee Boerneke, directly holds a stock option covering 101,193 common shares, with a $9.79 exercise price and expiration on May 12, 2036. The option was granted May 13, 2026; one-quarter vests and becomes exercisable on May 7, 2027, then one-forty-eighth vests monthly thereafter, subject to his continued service through each vesting date.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Boerneke Jeffrey Lee

Role General Counsel and Secretary

Type	Security	Shares	Price	Value
Holding	Stock Option (Right to Buy) F1	--	--	--

Holdings: Stock Option (Right to Buy) — 101,193 contracts (Direct)

Footnotes (1)

1. F1. The option was granted on May 13, 2026. 1/4th of the option shall vest and become exercisable on May 7, 2027, and 1/48th of the option shall vest and become exercisable monthly thereafter, subject to the Reporting Person's continued service through each vesting date.

Key Figures

Underlying shares subject to option: 101,193 shares Exercise price: $9.79 per share Option grant date: May 13, 2026 +4 more

7 metrics

Underlying shares subject to option 101,193 shares Direct stock option held by Jeffrey Lee Boerneke

Exercise price $9.79 per share Stock option

Option grant date May 13, 2026 Date the option was granted

Initial vesting date May 7, 2027 One-quarter of the option vests and becomes exercisable

Initial vesting portion 1/4 of the option Vests and becomes exercisable on May 7, 2027

Subsequent monthly vesting portion 1/48 of the option Vests monthly after May 7, 2027, subject to continued service

Option expiration date May 12, 2036 Expiration date of the stock option

Key Terms

Stock Option (Right to Buy), vest and become exercisable, continued service

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest and become exercisable financial

"shall vest and become exercisable"

continued service financial

"subject to the Reporting Person's continued service through each vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option did ASPE General Counsel Jeffrey Lee Boerneke report?

Jeffrey Lee Boerneke reported a directly held stock option covering 101,193 common shares, with a $9.79 exercise price and expiration on May 12, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Boerneke Jeffrey Lee

(Last) (First) (Middle)

10835 ROAD TO THE CURE, SUITE 100

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
10/29/2026

3. Issuer Name and Ticker or Trading Symbol
Aspen Neuroscience, Inc. [ ASPE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel and Secretary

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(1)	05/12/2036	Common Stock	101,193	$9.79	D

Explanation of Responses:

1. The option was granted on May 13, 2026. 1/4th of the option shall vest and become exercisable on May 7, 2027, and 1/48th of the option shall vest and become exercisable monthly thereafter, subject to the Reporting Person's continued service through each vesting date.

	By: /s/ Jeffrey L. Boerneke	10/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)